TAK-448 TAK-448 is a KISS1R protein agonist as a oligopeptide analog of kisspeptin. In animal model, TAK-448 can stimulate LH/FSH release, whereas continuous sc exposure rapidly down-regulates the pituitary-gonadal axis, with rapid reduction of T levels in a dose-dependent manner. Phase II clinical trials for the treatment of Prostate cancer was discontinued. In Dec 2016, Takeda terminated a phase II trial in Hypogonadism (In adults, In the elderly) in USA because the study did not meet the primary endpoints.
